Digital scans are very exciting and hopefully AHI (and other companies) will make huge inroads. I just looked up their technology and they show this for their Dermascan:
A sensitivity of 73% implies a 27% false negative rate. That is, 27% of users will have condition 'X" that the technology can't detect. (FWIW, industry standards of sensitivity and specificity around 90% are desirable). Approx quarter of users will get a false sense of security, IF they use this in isolation. I was rather shocked by this data and it only goes to show a second opinion is super critical, particularly where skin cancers are of concern. Having had 15 skin cancers myself, I think I will go to the dermatologist.
- Forums
- ASX - By Stock
- AHI Nasdaq Delisting Party
Digital scans are very exciting and hopefully AHI (and other...
-
-
- There are more pages in this discussion • 113 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AHI (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $22.73M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AHI (ASX) Chart |
Day chart unavailable